GNLX
HealthcareGenelux Corporation
$2.59-0.04 (-1.52%)
Prev Close
$2.63
Open
$2.66
High
$2.66
Low
$2.52
Volume
80.5K
Market Cap
$106.5M
P/E
—
Div Yield
—
Over the past 12 months, insider activity at Genelux Corporation (GNLX) has been exclusively selling, with 0 insider purchases totaling $0.00 and 6 insider sales totaling $183.6K. The most recent insider transaction was by Thomas John (director), who sold $57.9K worth of shares on Mar 3, 2026. Genelux Corporation operates in the Healthcare sector, within the Biotechnology industry, with a market cap of $106.5M.
Buys (12M)
0
$0.00
Sells (12M)
6
$183.6K
Net Activity
Net Seller
$183.6K
Active Insiders
4
last 12 mo
GNLX Price Chart
GNLX Insider Trading Activity
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| Mar 3, 2026↗ | Thomas John | director | Sell | 20,000 | $2.90 | $57.9K | 482,784 |
| Dec 1, 2025↗ | Thomas John | Director | Sell | 10,000 | $5.00 | $50.0K | 0 |
| Aug 21, 2025↗ | Cappello Joseph | Chief Technical Officer | Sell | 3,706 | $3.88 | $14.4K | 0 |
| Aug 21, 2025↗ | Yu Yong | SVP, Clinical Development | Sell | 4,192 | $3.82 | $16.0K | 0 |
| May 12, 2025↗ | Cappello Joseph | VP, Pharmaceutical Development | Sell | 4,737 | $2.92 | $13.8K | 0 |
| May 12, 2025↗ | Zindrick Thomas | President and CEO | Sell | 10,764 | $2.92 | $31.4K | 0 |
| Dec 30, 2024↗ | Tyree James L | Sell | 3,460 | $2.46 | $8.5K | 45,791 | |
| Dec 18, 2024↗ | Cappello Joseph | VP, Pharmaceutical Development | Sell | 6,300 | $2.34 | $14.7K | 14,653 |
| Dec 18, 2024↗ | Smalling Ralph | Head of Regulatory | Sell | 2,510 | $2.34 | $5.9K | 16,322 |
| Dec 18, 2024↗ | Zak Lourie S. | Chief Financial Officer | Sell | 2,103 | $2.34 | $4.9K | 40,802 |
| Dec 18, 2024↗ | Zindrick Thomas | President and CEO | Sell | 14,315 | $2.34 | $33.5K | 37,372 |
| Sep 13, 2024↗ | Szalay Aladar | Sell | 64,857 | $2.65 | $171.7K | 632,901 | |
| Sep 12, 2024↗ | Tyree James L | Sell | 1,730 | $2.60 | $4.5K | 47,521 | |
| Sep 11, 2024↗ | Szalay Aladar | Sell | 75,143 | $2.62 | $196.6K | 716,438 | |
| Sep 6, 2024↗ | Szalay Aladar | Sell | 42,818 | $2.09 | $89.6K | 739,821 | |
| Aug 30, 2024↗ | Szalay Aladar | Sell | 265,552 | $2.09 | $554.4K | 1,032,270 | |
| Aug 27, 2024↗ | Szalay Aladar | Sell | 91,630 | $2.19 | $200.3K | 1,099,820 | |
| Jul 8, 2024↗ | Jewett Caroline | Head of Quality | Sell | 4,961 | $2.12 | $10.5K | 16,174 |
| Jul 8, 2024↗ | Ryder Sean | General Counsel | Sell | 5,496 | $2.12 | $11.7K | 19,388 |
| Jul 8, 2024↗ | Yu Yong | VP, Clinical Trial Operations | Sell | 6,849 | $2.12 | $14.5K | 10,869 |
| May 15, 2024↗ | Szalay Aladar | Sell | 35,966 | $3.63 | $130.4K | 1,172,340 | |
| May 9, 2024↗ | Szalay Aladar | Sell | 19,944 | $3.78 | $75.3K | 1,189,710 | |
| May 1, 2024↗ | Szalay Aladar | Sell | 59,999 | $3.23 | $193.9K | 1,249,330 | |
| Apr 24, 2024↗ | Szalay Aladar | Sell | 44,395 | $3.51 | $155.6K | 1,285,790 | |
| Apr 18, 2024↗ | Szalay Aladar | Sell | 71,420 | $3.59 | $256.2K | 1,322,860 | |
| Dec 18, 2023↗ | Yu Yong | VP, Clinical Trial Operations | Sell | 32,535 | $13.16 | $428.2K | 5,803 |
| Dec 14, 2023↗ | Thomas John | Director | Sell | 9,000 | $13.38 | $120.4K | 465,387 |
| Dec 14, 2023↗ | Tyree James L | Director | Sell | 9,000 | $13.22 | $119.0K | 6,807 |
| Dec 8, 2023↗ | Yu Yong | VP, Clinical Trial Operations | Sell | 36,800 | $11.85 | $436.0K | 32,535 |
| Nov 22, 2023↗ | Yu Yong | VP, Clinical Trial Operations | Sell | 18,665 | $10.26 | $191.6K | 69,335 |
| Nov 21, 2023↗ | Yu Yong | VP, Clinical Trial Operations | Sell | 18,135 | $11.60 | $210.4K | 102,594 |
| Oct 26, 2023↗ | Szalay Aladar | 10% Owner | Sell | 5,704 | $19.40 | $110.6K | 1,371,540 |
| Oct 25, 2023↗ | Szalay Aladar | 10% Owner | Sell | 49,987 | $19.97 | $998.4K | 1,377,250 |
| Oct 25, 2023↗ | Yu Yong | VP, Clinical Trial Operations | Sell | 5,200 | $19.11 | $99.4K | 106,135 |
| Oct 16, 2023↗ | Thomas John | Director | Sell | 3,333 | $20.71 | $69.0K | 473,341 |
| Oct 11, 2023↗ | Yu Yong | VP, Clinical Trial Operations | Sell | 5,200 | $22.01 | $114.5K | 106,535 |
| Oct 10, 2023↗ | Szalay Aladar | 10% Owner | Sell | 14,251 | $24.93 | $355.2K | 1,428,220 |
| Oct 4, 2023↗ | Szalay Aladar | 10% Owner | Sell | 75,690 | $25.49 | $1.93M | 1,441,490 |
| Sep 29, 2023↗ | Szalay Aladar | 10% Owner | Sell | 13,546 | $24.41 | $330.7K | 1,519,470 |
| Sep 27, 2023↗ | Szalay Aladar | 10% Owner | Sell | 42,263 | $24.38 | $1.03M | 1,569,040 |
| Sep 27, 2023↗ | Yu Yong | VP, Clinical Trial Operations | Sell | 5,200 | $23.56 | $122.5K | 109,452 |
| Sep 25, 2023↗ | Szalay Aladar | 10% Owner | Sell | 16,591 | $27.85 | $462.0K | 1,586,710 |
| Sep 21, 2023↗ | Ryder Sean | General Counsel | Sell | 10,000 | $30.00 | $300.0K | 572 |
| Sep 21, 2023↗ | Yu Yong | VP, Clinical Trial Operations | Sell | 6,000 | $27.96 | $167.8K | 106,135 |
| Sep 20, 2023↗ | Szalay Aladar | 10% Owner | Sell | 62,459 | $24.92 | $1.56M | 8,247 |
| Sep 18, 2023↗ | Thomas John | Director | Sell | 6,667 | $23.45 | $156.3K | 480,215 |
| Sep 18, 2023↗ | Yu Yong | VP, Clinical Trial Operations | Sell | 10,400 | $21.89 | $227.6K | 110,810 |
| Sep 15, 2023↗ | Szalay Aladar | 10% Owner | Sell | 44,308 | $21.80 | $965.9K | 63,883 |
| Sep 15, 2023↗ | Yu Yong | VP, Clinical Trial Operations | Sell | 29,800 | $21.14 | $629.9K | 106,135 |
| Sep 14, 2023↗ | Smither John W | Director | Sell | 900 | $20.78 | $18.7K | 6,920 |
Showing 1–50 of 61
1 / 2
GNLX Insider Buying Activity
The following table shows recent insider purchases of Genelux Corporation (GNLX) stock reported via SEC Form 4 filings.
No insider buying activity found for GNLX in the last 12 months.
GNLX Insider Selling Activity
The following table shows recent insider sales of Genelux Corporation (GNLX) stock reported via SEC Form 4 filings.
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| Mar 3, 2026↗ | Thomas John | director | Sell | 20,000 | $2.90 | $57.9K | 482,784 |
| Dec 1, 2025↗ | Thomas John | Director | Sell | 10,000 | $5.00 | $50.0K | 0 |
| Aug 21, 2025↗ | Cappello Joseph | Chief Technical Officer | Sell | 3,706 | $3.88 | $14.4K | 0 |
| Aug 21, 2025↗ | Yu Yong | SVP, Clinical Development | Sell | 4,192 | $3.82 | $16.0K | 0 |
| May 12, 2025↗ | Cappello Joseph | VP, Pharmaceutical Development | Sell | 4,737 | $2.92 | $13.8K | 0 |
| May 12, 2025↗ | Zindrick Thomas | President and CEO | Sell | 10,764 | $2.92 | $31.4K | 0 |
| Dec 30, 2024↗ | Tyree James L | Sell | 3,460 | $2.46 | $8.5K | 45,791 | |
| Dec 18, 2024↗ | Cappello Joseph | VP, Pharmaceutical Development | Sell | 6,300 | $2.34 | $14.7K | 14,653 |
| Dec 18, 2024↗ | Smalling Ralph | Head of Regulatory | Sell | 2,510 | $2.34 | $5.9K | 16,322 |
| Dec 18, 2024↗ | Zak Lourie S. | Chief Financial Officer | Sell | 2,103 | $2.34 | $4.9K | 40,802 |
| Dec 18, 2024↗ | Zindrick Thomas | President and CEO | Sell | 14,315 | $2.34 | $33.5K | 37,372 |
| Sep 13, 2024↗ | Szalay Aladar | Sell | 64,857 | $2.65 | $171.7K | 632,901 | |
| Sep 12, 2024↗ | Tyree James L | Sell | 1,730 | $2.60 | $4.5K | 47,521 | |
| Sep 11, 2024↗ | Szalay Aladar | Sell | 75,143 | $2.62 | $196.6K | 716,438 | |
| Sep 6, 2024↗ | Szalay Aladar | Sell | 42,818 | $2.09 | $89.6K | 739,821 | |
| Aug 30, 2024↗ | Szalay Aladar | Sell | 265,552 | $2.09 | $554.4K | 1,032,270 | |
| Aug 27, 2024↗ | Szalay Aladar | Sell | 91,630 | $2.19 | $200.3K | 1,099,820 | |
| Jul 8, 2024↗ | Jewett Caroline | Head of Quality | Sell | 4,961 | $2.12 | $10.5K | 16,174 |
| Jul 8, 2024↗ | Ryder Sean | General Counsel | Sell | 5,496 | $2.12 | $11.7K | 19,388 |
| Jul 8, 2024↗ | Yu Yong | VP, Clinical Trial Operations | Sell | 6,849 | $2.12 | $14.5K | 10,869 |
| May 15, 2024↗ | Szalay Aladar | Sell | 35,966 | $3.63 | $130.4K | 1,172,340 | |
| May 9, 2024↗ | Szalay Aladar | Sell | 19,944 | $3.78 | $75.3K | 1,189,710 | |
| May 1, 2024↗ | Szalay Aladar | Sell | 59,999 | $3.23 | $193.9K | 1,249,330 | |
| Apr 24, 2024↗ | Szalay Aladar | Sell | 44,395 | $3.51 | $155.6K | 1,285,790 | |
| Apr 18, 2024↗ | Szalay Aladar | Sell | 71,420 | $3.59 | $256.2K | 1,322,860 | |
| Dec 18, 2023↗ | Yu Yong | VP, Clinical Trial Operations | Sell | 32,535 | $13.16 | $428.2K | 5,803 |
| Dec 14, 2023↗ | Thomas John | Director | Sell | 9,000 | $13.38 | $120.4K | 465,387 |
| Dec 14, 2023↗ | Tyree James L | Director | Sell | 9,000 | $13.22 | $119.0K | 6,807 |
| Dec 8, 2023↗ | Yu Yong | VP, Clinical Trial Operations | Sell | 36,800 | $11.85 | $436.0K | 32,535 |
| Nov 22, 2023↗ | Yu Yong | VP, Clinical Trial Operations | Sell | 18,665 | $10.26 | $191.6K | 69,335 |
| Nov 21, 2023↗ | Yu Yong | VP, Clinical Trial Operations | Sell | 18,135 | $11.60 | $210.4K | 102,594 |
| Oct 26, 2023↗ | Szalay Aladar | 10% Owner | Sell | 5,704 | $19.40 | $110.6K | 1,371,540 |
| Oct 25, 2023↗ | Szalay Aladar | 10% Owner | Sell | 49,987 | $19.97 | $998.4K | 1,377,250 |
| Oct 25, 2023↗ | Yu Yong | VP, Clinical Trial Operations | Sell | 5,200 | $19.11 | $99.4K | 106,135 |
| Oct 16, 2023↗ | Thomas John | Director | Sell | 3,333 | $20.71 | $69.0K | 473,341 |
| Oct 11, 2023↗ | Yu Yong | VP, Clinical Trial Operations | Sell | 5,200 | $22.01 | $114.5K | 106,535 |
| Oct 10, 2023↗ | Szalay Aladar | 10% Owner | Sell | 14,251 | $24.93 | $355.2K | 1,428,220 |
| Oct 4, 2023↗ | Szalay Aladar | 10% Owner | Sell | 75,690 | $25.49 | $1.93M | 1,441,490 |
| Sep 29, 2023↗ | Szalay Aladar | 10% Owner | Sell | 13,546 | $24.41 | $330.7K | 1,519,470 |
| Sep 27, 2023↗ | Szalay Aladar | 10% Owner | Sell | 42,263 | $24.38 | $1.03M | 1,569,040 |
| Sep 27, 2023↗ | Yu Yong | VP, Clinical Trial Operations | Sell | 5,200 | $23.56 | $122.5K | 109,452 |
| Sep 25, 2023↗ | Szalay Aladar | 10% Owner | Sell | 16,591 | $27.85 | $462.0K | 1,586,710 |
| Sep 21, 2023↗ | Ryder Sean | General Counsel | Sell | 10,000 | $30.00 | $300.0K | 572 |
| Sep 21, 2023↗ | Yu Yong | VP, Clinical Trial Operations | Sell | 6,000 | $27.96 | $167.8K | 106,135 |
| Sep 20, 2023↗ | Szalay Aladar | 10% Owner | Sell | 62,459 | $24.92 | $1.56M | 8,247 |
| Sep 18, 2023↗ | Thomas John | Director | Sell | 6,667 | $23.45 | $156.3K | 480,215 |
| Sep 18, 2023↗ | Yu Yong | VP, Clinical Trial Operations | Sell | 10,400 | $21.89 | $227.6K | 110,810 |
| Sep 15, 2023↗ | Szalay Aladar | 10% Owner | Sell | 44,308 | $21.80 | $965.9K | 63,883 |
| Sep 15, 2023↗ | Yu Yong | VP, Clinical Trial Operations | Sell | 29,800 | $21.14 | $629.9K | 106,135 |
| Sep 14, 2023↗ | Smither John W | Director | Sell | 900 | $20.78 | $18.7K | 6,920 |
GNLX Insiders
Mirabelli Mary
2 tradesLast: May 29, 2024
Smither John W
2 tradesLast: May 29, 2024
Thomas John
2 tradesLast: May 29, 2024
Similar Stocks to GNLX
VRTX
Vertex Pharmaceuticals Incorporated
$470.20-1.66%
$121.44B
REGN
Regeneron Pharmaceuticals, Inc.
$743.51-0.41%
$77.57B
ALNY
Alnylam Pharmaceuticals, Inc.
$313.45-1.19%
$42.07B
INSM
Insmed Incorporated
$139.06-0.33%
$30.07B
UTHR
United Therapeutics Corporation
$536.12+0.97%
$23.50B
MRNA
Moderna, Inc.
$52.56-1.89%
$20.76B
ROIV
Roivant Sciences Ltd.
$28.06-1.44%
$20.08B
RPRX
Royalty Pharma plc
$45.65-0.57%
$19.56B